Anti-Lassa Virus, Nucleoprotein [Clone 1LV13] – Purified No Carrier Protein

Anti-Lassa Virus, Nucleoprotein [Clone 1LV13] – Purified No Carrier Protein

Product No.: L349

- -
- -
Clone
ILV13
Target
Nucleoprotein
Formats AvailableView All
Product Type
Hybridoma Monoclonal Antibody
Alternate Names
Lassa, LASV, Lassa Virus
Isotype
Mouse IgG1 κ
Applications
ELISA
,
Lateral Flow

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Lassa Virus
Host Species
Mouse
Product Concentration
≥1.0 mg/ml
Purity
≥90%
State of Matter
Liquid
Storage and Handling
This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.
Regulatory Status
Research Use Only
Country of Origin
USA
Shipping
2-8°C Wet Ice
Applications and Recommended Usage?
Quality Tested by Leinco
ELISA,
Lateral Flow
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
Anti-Lassa Virus (Clone ILV13) is specific for the Nucleoprotein of Lassa Virus.
Background
Lassa virus, a member of the Arenaviridae family, is a zoonotic pathogen primarily found in West Africa, particularly in regions such as Nigeria, Sierra Leone, and Liberia. The virus is transmitted to humans primarily through contact with rodent excreta or consumption of contaminated food. Lassa fever, the disease caused by the virus, manifests with flu-like symptoms initially but can progress to severe complications including hemorrhage and organ failure. Timely diagnosis is crucial for effective management, typically involving laboratory tests such as enzyme-linked immunosorbent assay (ELISA) or reverse transcriptase-polymerase chain reaction (RT-PCR) to detect viral antigens or genetic material in blood or tissue samples. Early detection allows for prompt treatment with antiviral medications and supportive care, significantly improving patient outcomes and reducing mortality rates associated with Lassa fever.
Research Area
Category A Pathogens
.
Infectious Disease
.
Matched Pair
.
Viral
.
IVD Raw Material

References & Citations

1. Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of High-Consequence Pathogens and Pathology (DHCPP), Viral Special Pathogens Branch (VSPB). Link
Indirect Elisa Protocol
Lateral Flow

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.